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Abstract: Malignant ascites (MA) is most commonly observed in
patients scheduled for epithelial ovarian cancer (EOC) surgery and is
supposed as a major risk factor promoting perioperative hemodynamic
deterioration. We aimed to assess the hemodynamic consequences of MA
onsystemic circulation inpatients undergoing cytoreductiveEOCsurgery.
This study is a predefined post-hoc analysis of a randomized con-
trolled pilot trial comparing intravenous solutions within a goal-directed
algorithm to optimize hemodynamic therapy in patients undergoing
cytoreductive EOC surgery. Ascites was used to stratify the EOC patients
prior to randomization in themain study.We analyzed 2 groups according
to the amount of ascites (NLAS: none or low ascites [<500mL] vs HAS:
high ascites group [>500mL]). Differences in hemodynamic variables
with respect to time were analyzed using nonparametric analysis for
longitudinal data and multivariate generalized estimating equation adjust-
ing the analysis for the randomized study groups of the main study.
Atotalof31patients intheNLASand16patientsintheHASgroupwere
analyzed. Although cardiac output was not different between groups
suggesting a similar circulatorybloodflow, theHASgroup revealedhigher
heart rates and lower stroke volumes during surgery. There were no
differences in pressure-based hemodynamic variables. In the HAS group,
fluiddemands, reflectedby the timeto reindicationofafluidchallenge after
preload optimization, increased steadily, whereas stroke volume could notch, BSc, Jalid Seho
d Aarne Feldheiser, MD
associations of the type of fluid replacement with hemodynamic con-
sequences were particularly observed in the HAS group, in which transfu-
sionoffreshfrozenplasma(FFP)wasassociated toanimprovedcirculatory
flow and reduced vasopressor and fluid demands, whereas the adminis-
tration of artificial infusion solutions was related to opposite effects.
Malignant ascites >500mL implies increased fluid demands and
substantial alterations in circulatory blood flow during cancer surgery.
Fresh frozen plasma transfusion promotes recovering hemodynamic
stability in patients with malignant ascites >500mL, in whom artificial
infusion solutions could not prevent from hemodynamic deterioration.
(Medicine 94(49):e2108)
Abbreviations: ASA = American Society of Anesthesiology, CO =
cardiac output, CVP = central venous pressure, EOC = epithelial
ovarian cancer, FFP = fresh frozen plasma, FIGO = Fe´de´ration
Internationale de Gyne´cologie et d’Obste´trique, FTc = corrected
flow time, GDT = goal-directed therapy, GEE = generalized
estimating equations, HAS = high ascites, HR = heart rate, MA =
malignant ascites, MAP = mean arterial pressure, NE =
norepinephrine, NparLD = nonparametric analysis for
longitudinal data, NLAS = none or low ascites, ODM =
oesophageal Doppler monitor, OR = odds ratio, POSSUM =ive Severity Score for the enumeration of
ty, SV = stroke volume, TTRI = time to
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INTRODUCTION
E pithelial ovarian cancer (EOC) is the most common cause ofmalignant ascites (MA).1 Malignant ascites is frequently
observed in advanced stages of EOC and indicates tumor
dissemination in the peritoneal cavity.2 The pathogenesis is
complex, multifactorial determined, and primarily involves an
increased production of peritoneal fluid due to altered vascular
permeability and increased peritoneal neovascularization com-
bined with an impaired lymphatic drainage from the peritoneal
cavity due to obstructed lymphatic channels at a diaphragmatic
level.3–5
As contemporary evidence on paracentesis prior to surgery
is still limited and peritoneal fluid reaccumulates quickly,2
50% of the patients scheduled for EOC surgery present with
a substantial amount of MA on the day of surgery.6,7 Malignant
ascites has recently been shown as a major determinant for the
interdisciplinary clinical course in patients with EOC under-
going cytoreductive surgery with a significant impact on
anesthesiological treatment and postoperative morbidity.6
Whereas major perioperative circulatory complications were
of a moderate frequency in patients with none or low ascites
(<500mL), these were very frequently observed in patients
with high amount of ascites (>500mL).6
In this regard, MA >500mL is supposed as a major risk
factor promoting perioperative hemodynamic deterioration, but
detailed data of hemodynamic consequences ofMA on systemic
circulation in patients undergoing cytoreductive EOC surgery
are still limited. Furthermore, data on the appropriate type of
intraoperative fluid replacement with respect to hemodynamic
stability in patients with high amounts ofMA are crucial but still
not available.
Therefore, this study aimed to compare a none or low
ascites group (<500mL) with a high ascites group (>500mL)
regarding time courses of hemodynamic variables, time courses
of variables of fluid, transfusion, and vasopressor demands; and
to investigate the relation of administered artificial infusion
solutions and fresh frozen plasma with hemodynamic variables
as well as vasopressor and fluid demands in patients undergoing
EOC surgery.
METHODS
This study is a predefined post-hoc analysis of a previously
published randomized controlled pilot trial comparing a
balanced crystalloid with a balanced colloid within a goal-
directed hemodynamic algorithm in patients with advanced
primary epithelial ovarian cancer undergoing cytoreductive
surgery (BalaCriCo trial, ISRCTN 53154834).8 This subana-
lysis investigates the significance of malignant ascites on
systemic circulation during surgery that was not reported in
the previous publication of the main study.
Ethical approval was given by the Ethical Committee (No.
EK 12 581/08) and the competent German authority (No.
4034705) and was internationally subscribed. The trial was
conducted at Charite´, University Medicine Berlin, Campus
Virchow Klinikum, Berlin, Germany, from May 2009 to March
2011 and written informed consent was obtained from
all patients.
Study Design and Patients
As the main study was a randomized controlled trial the
Hunsicker et alpatients were randomly assigned to receive either a balanced
crystalloid or a balanced colloid solution for intraoperative
hemodynamic optimization within a goal-directed algorithm.
2 | www.md-journal.comOn the day prior surgery, before randomization a consultant
gynecologist performed an abdominal ultrasound examination
including screening for ascites. If ascitic fluid was present, the
amount was estimated by the formula: measure the maximal fluid
depth or depth of the deepest pocket (AP diameter) (cm) 
100¼ volume (mL). The result of the ultrasound examination
in relation to ascites was the stratification criteria during the
randomization process. According to the presence and amount of
ascites we analyzed 2 groups in this subanalysis (NLAS: none or
low ascites [<500 mL] vs HAS: high ascites group [>500 mL]).
The entire data for this subanalysis were obtained from the
per-protocol groups of the BalaCriCo trial resulting in a subset
of 48 patients. For this subanalysis, the patients of the per-
protocol groups were merged and regrouped by ascites. One
patient had to be excluded, as preoperative ultrasound screening
was not performed. Consequently, a subset of 47 patients was
eligible for statistical analysis (Flow Diagram Fig. 1).
Intraoperative hemodynamic Management
The hemodynamic management was performed according
to an outcome-based goal-directed hemodynamic algorithm
guided by the oesophageal Doppler monitor (ODM, Car-
dioQ-ODMTM, Deltex Medical, Chichester, UK).9
Briefly, after induction of anesthesia and establishing the
hemodynamic monitoring hemodynamic optimization was
started. First an initial fluid challenge of 200 mL of intravenous
study fluid was given over 5 min. If stroke volume measured by
ODM (SVODM) failed to rise by10% no further fluid challenge
was given. If SVODM increased of 10%, additional fluid chal-
lenges with an intravenous bolus of 200 mL were given until no
further increase of SVODM of 10% could be measured. After a
period of 15 min or clinically relevant hemodynamic changes of
mean arterial pressure or heart rate SVODM was measured again
and a decrease of>10% compared with SVODM after the last fluid
challenge reindicated a further fluid challenge.
Fluid challenges were performed during the entire course
of surgery as indicated by the goal-directed hemodynamic
algorithm and conducted either with a balanced crystalloid
(Jonosteril, Fresenius Kabi, Bad Homburg, Germany) or a
balanced colloid solution (Volulyte, 6%, 130/0.4, Fresenius
Kabi) according to the randomization. At the maximum dose
of the study fluid (when 50 mL kg1 body weight was reached),
the fluid challenges were conducted by transfusion of fresh-
frozen plasma (FFP). In addition, mean arterial pressure was
maintained with bolus or continuous administration of norepi-
nephrine and positive inotropic drugs were given if the cardiac
index dropped <2.5 L min1 m2, while stroke volume could
not be raised further by volume administration.
Endpoints
We compared 2 groups (NLAS group: none or low ascites
[<500 mL] vs HAS group: high ascites group [>500 mL])
regarding: (1) time courses of hemodynamic variables includ-
ing: heart rate (HR), stroke volume (SV), cardiac output (CO),
corrected flow time (FTc), mean arterial pressure (MAP), and
central venous pressure (CVP); (2) time courses of variables of
fluid, transfusion, and vasopressor demands including: time to
reindication of a fluid challenge (TTRI), total volume adminis-
tered within the goal-directed therapy, transfusion of fresh
frozen plasma (FFP), and norepinephrine (NE) requirements.
Medicine  Volume 94, Number 49, December 2015Time to reindication of a fluid challenge was introduced as
a new approach to standardized characterize the patient’s
individual fluid demands at different time points during surgery
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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FIGURE 1. Advanced flow diagram of the study with respect to tchallenge was calculated as the time frame from preload
optimization to reindication of a fluid challenge within the
used goal-directed algorithm (Fig. 2).
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.Furthermore, we investigated the relation of time courses
subanalysis.of SV, HR, NE, and TTRI with the time courses of adminis-
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Timeline
FIGURE 2. Determination of time to reindication (TTRI) of a fluid
challenge within the goal-directed algorithm. During an optim-
ization trial fluid challenges (FC) with 200mL of balanced crystal-
loid or colloid or fresh frozen plasma were administered. If a fluid
challenge results in an increase of stroke volume of >10%, further
FC are given until no further increase of SV 10% could be
measured. At this time the patient is considered as preload
optimized. After a period of 15 min or clinically relevant hemo-
dynamic changes of mean arterial pressure or heart rate SV is
measured again and a decrease of >10% compared with SV after
the last fluid challenge reindicated an optimization trial. The TTRI
is calculated as the time frame from preload optimization to
Hunsicker et alStatistical Analysis
To check the present data distributions, we used the
graphic inspection by box plots, QQ plots, and histograms.
Furthermore, we arithmetical examined the distributions by
skewness. Because of limited sample sizes and non-normal
distributions of the observations, data were expressed as
median (25%, 75% quartiles), or frequencies (%), respect-
ively. Therefore, differences between ascites groups in terms
of continuous data were tested by using the Mann–Whitney U
test for independent groups, whereas frequencies were tested
by Fisher’s exact test.
Due to the repeated measurements, differences in hemo-
dynamic variables with respect to time between ascites groups
were analyzed by using nonparametric analysis for longitudinal
data (NparLD) as described by Brunner and colleagues.10
Therefore, all time points were simultaneously compared on
the corresponding response curves. The following hypotheses
have been tested with those analyses: differences between
groups over time (group) and systematic changes in time
separately for every group (time course). These analyses were
complemented by adjusting for randomized study groups (crys-
talloid and colloid intervention group) of the main study (group
(adjusted

)) using the general estimating equation (GEE) as
described by Liang and Zeger.11 To estimate the required
sample size for multiple analysis with continuous outcomes,
we followed the rule of Harrell for orientation.12 In this regard,
the total sample size should be divided by 10 to 20 to obtain the
number of predictors for a stable model. In our case, we
included 48 patients for analysis resulting in a maximum of
2 to 3 predictors allowed. In this respect, the minimum require-
ments were fulfilled as we included 2 independent variables
(ascites groups and randomized study groups) in the
reindication of the next fluid challenge FC¼fluid challenge,
SV¼ stroke volume, TTRI¼ time to reindication.GEE model.
To study the association of time courses of administration
of intravenous infusion solutions and transfusion of fresh frozen
4 | www.md-journal.complasma with the time courses of SV, HR, NE, and TTRI during
surgery, also the above methods for repeated measurements
were used. Adjusted odds ratios (OR) with 95% confidence
interval were calculated. Regarding the clinical interpretation,
ORs of intravenous infusion solutions and fresh frozen plasma
were scaled for the administration of 1 fluid challenge (200 mL)
and 1 unit, respectively.
A 2-tailed P value of 0.05 was considered statistically
significant. All numerical calculations were performed with
IBM#SPSS# Statistics, Version 20,# Copyright 1989, 2010
SPSS Inc. and the free software from R project for Statistical
Computing, Version 3.0.2 (R-packages used: ‘‘foreign’’ release




A total of 31 patients in the NLAS and 16 patients in the
HAS group were analyzed. There were no differences in
baseline characteristics except for lower preoperative albumin
levels in the HAS group (Table 1). Patients randomized in the
main study to receive balanced crystalloid or colloid were
similarly distributed among NLAS and HAS groups
(P¼ 0.760) (Table 2). The amount of malignant ascites in
the NLAS and HAS groups was 0 (0; 250) and 2150 (1500;
3875) mL (P< 0.001), respectively (Table 2). Whereas scores
assessing preoperative physiological condition and comorbid-
ities were not different between groups, patients in the HAS
group had a more progressed cancer disease and a higher risk
prediction for perioperative morbidity and mortality. With
respect to hemodynamics before and after induction of
anesthesia, the HAS group had higher heart rates compared
with the NLAS group, whereas mean arterial pressure was
not different.
Comparison of Time Courses of Hemodynamic
Variables
While CO was not different between ascites groups
suggesting a similar circulatory flow during the course of
surgery, the HAS group revealed higher HR, lower SV, and
lower FTc indicating that circulatory flow was not equivalent
between groups (Fig. 3). There were no differences in pressure-
based hemodynamic variables such as MAP and CVP.
In the HAS group, SV and FTc started to decrease steadily
after beginning of surgery and could not be maintained at
baseline reaching critically reduced values after 1.5 h of
surgery. In contrast, in the NLAS group, SV and FTc could
be mainly maintained and did not change significantly during
the course of surgery. Although the HAS group had higher HR
compared to the NLAS group, both groups showed a consecu-
tive increase of HR during surgery. Generalized estimating
equations regression analysis confirmed that the observed
differences in time courses of HR, SV, and FTc between NLAS
and HAS groups were independently associated to ascites
groups after adjusting for the randomized study groups of the
main study.
Comparison of Time Courses of Variables of
Fluid, Transfusion, and Vasopressor Demands
Medicine  Volume 94, Number 49, December 2015During surgery, the time to reindication of a fluid chal-
lenge (TTRI) was significantly shorter in the HAS group. In the
HAS group, after beginning of surgery TTRI decreased steadily
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.






(n¼ 16) P Value
Age (years) 53.0 (45.0; 63.0) 57.0 (48.8; 65.3) 0.370

Body mass index (kg m2) 25.5 (23.0; 30.1) 24.8 (23.1; 28.5) 1.000
Preoperative albumin (g dL1) 3.6 (3.5; 3.8) 3.1 (2.6; 3.2) <0.001
American Society of Anesthesiology (ASA)
ASA Physical Status I, n (%) 2 (6.5) 1 (6.3) 0.104y
ASA Physical Status II, n (%) 19 (61.3) 5 (31.3)
ASA Physical Status III, n (%) 10 (32.3) 10 (62.5)
Charlson comorbidity index 6.0 (6.0; 6.0) 6.0 (6.0; 6.8) 0.416

Chronic medications
Beta blocker, n (%) 9 (29.0) 1 (6.3) 0.131y
Angiotensin converting enzyme inhibitors, n (%) 6 (19.4) 1 (6.3) 0.396y
Angiotensin type 1 receptor antagonists, n (%) 1 (3.2) 2 (12.5) 0.264y
Statins, n (%) 4 (12.9) 2 (12.5) 1.000y
Diuretics, n (%) 4 (12.9) 2 (12.5) 1.000y
Other medications, n (%) 6 (19.4) 3 (18.8) 1.000y
Preoperative fasting of
Fluids (min) 660 (420; 848) 705 (510; 990) 0.517

Solids (min) 1215 (1048; 1510) 1388 (1140; 1440 0.994

ASA¼American Society of Anesthesiology, HAS¼ high ascites, NLAS¼ none or low ascites.
Data are shown as median (25%; 75%) quartiles or as n (%) patients.
P values calculated using the exact Wilcoxon–Mann–Whitney test

and Fisher’s exact testy as appropriate.
Medicine  Volume 94, Number 49, December 2015 Hemodynamic Consequences of Malignant Ascites in EOC Surgeryreaching minimum values after 2 h and then showed an increase
again reaching baseline values at the end of surgery (Fig. 4). In
contrast, in the NLAS group the TTRI increased slightly and
showed no substantial decrease during surgery. Patients in the
HAS group received a higher amount of total volume within the
GDT with more fresh frozen plasma (FFP) and red packed cells
administered (Table 2, Fig. 4). Although total volume admin-
istration was similar between ascites groups during the first hour
of surgery, the curves started to diverge 1 h after beginning of
surgery. Furthermore, the HAS group required higher norepi-
nephrine administrations during surgery, resulting in higher
cumulative doses at the end of surgery (Table 2, Fig. 4).
Similarly to total volume administration, there was a substantial
increase in NE doses after 1.5 h in the HAS group. According to
GEE regression analysis, the differences in TTRI, total volume
administered, transfusion of FFP and NE administration during
surgery were independently associated to ascites groups after
adjusting for the randomized study groups of the main study.
Relation of the Type of Fluid Replacement with
SV, HR, NE, and TTRI
Clinically relevant associations of the type of fluid repla-
cement with hemodynamic consequences were particularly
observed in the HAS group (Fig. 5). In the HAS group,
administration of fresh frozen plasma was associated with
increases of SV, prolongations of TTRI and decreases of HR
and NE administration. In contrast, the transfusion of intrave-
nous infusion solutions was associated with decreases of SV,
shortenings of TTRI and increases of HR and NE adminis-
tration. Although the relations were less considerable in the
LAS group, the administration of intravenous infusion solutions
was related to decreases of SV and increases of NE
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.administration, whereas FFP transfusion was related to
decreased NE administration.
DISCUSSION
Our findings address important issues regarding hemody-
namic consequences within a goal-directed algorithm in
patients with malignant ascites undergoing EOC surgery.
The main findings of the study are (1) that although cardiac
output was not different, higher heart rates, lower stroke
volumes, and lower corrected flow times in the high ascites
group indicate that circulatory flow was not equivalent between
groups; (2) that in the high ascites group after start of surgery
fluid demands increased steadily whereas stroke volume
decreased continuously resulting in hemodynamic instability
after 1.5 h of surgery with massive fluid and vasopressor
requirements; (3) that clinically relevant associations of the
type of fluid replacement were particularly observed in the high
ascites group, in which transfusion of FFP was associated to an
improved circulatory flow, hemodynamic stability, and reduced
fluid demands, whereas the administration of artificial infusion
solutions was related to opposite effects.
Although cardiac output was similar in NLAS and HAS
groups, stroke volume (SV) and heart rate (HR) as determinants
of circulating blood flow showed substantial differences during
the course of surgery. Whereas a maintained SV during surgery
has been widely shown to improve outcome13 and intraopera-
tive tachycardia was related to increased mortality,14 little is
known about consequences of an elevated HR below tachycar-
dic threshold. However, recent data indicate that lower HR is
related to improved microvascular blood flow and blood flow
heterogeneity suggesting that HR is not only a multiplier of SV
to generate cardiac output.15 In this respect, despite a similar
www.md-journal.com | 5






(n¼ 16) P Value
Randomized to balanced crystalloid group
(vs balanced colloid), n (%)
15 (48.4) 9 (56.3) 0.760y
Amount of malignant ascites (mL) 0 (0; 250) 2150 (1500; 3875) <0.001

Physiologic and Operative Severity Score for the enumeration of Mortality and Morbidity (POSSUM)
Possum physiologic score 14.0 (13.0; 16.0) 14.5 (13.0; 17.8) 0.329

Possum operative score 31.0 (27.0; 34.0) 34.0 (31.0; 37.0) 0.047

Possum score 46.0 (43.0; 48.0) 50.0 (46.0; 54.5) 0.038

Possum score risk prediction morbidity (%) 91.5 (84.8; 94.2) 96.0 (91.6; 98.0) 0.033

Possum score risk prediction mortality (%) 15.2 (9.7; 20.0) 24.4 (14.9; 39.9) 0.044

FIGO classification
Stadium 1, n (%) 5 (16) 0 (0) <0.001y
Stadium 2, n (%) 6 (19) 0 (0)
Stadium 3a, n (%) 5 (16) 0 (0)
Stadium 3b, n (%) 4 (13) 4 (25)
Stadium 3c, n (%) 5 (16) 10 (63)
Tumor dissemination pattern
Level 1, pelvic, n (%) 23 (82) 16 (100) 0.141y
Level 2, extrapelvic (colon, small bowel), n (%) 15 (54) 14 (93) 0.015y
Level 3, extrapelvic (upper abdomen), n (%) 11 (39) 13 (87) 0.004y
Hemodynamics before induction of anesthesia
Mean arterial pressure (mm Hg) 77 (67; 90) 81 (71; 85) 0.919

Heart rate (min1) 80 (74; 98) 89 (87; 101) 0.049
Hemodynamics after induction of anesthesia
Mean arterial pressure (mm Hg) 73 (66; 84) 71 (64; 79) 0.500

Heart rate (min1) 70 (65; 82) 86 (72; 92) 0.034
Duration of surgery (hh: min) 4:00 (3:15; 5:10) 4:45 (3:33; 5:50) 0.262

Epidural anesthesia, n (%) 30 (97) 15 (94) 1.000y
Infusion solutions and blood product administration
Total administered volume 5320 (4180; 6620) 7522 (6598; 9172) 0.004

Study medication (mL) 3000 (2450; 3425) 3200 (2812; 3925) 0.242

Red packed cells (mL) 0 (0; 590) 600 (115; 1430) 0.009

Fresh frozen plasma (mL) 920 (0; 1592) 2080 (923; 3960) 0.007

Patients with intraoperative transfusion of red
packed cells, n (%)
12 (38.7) 12 (75.0) 0.030y
Patients with intraoperative transfusions
of fresh frozen plasma, n (%)
22 (71.0) 14 (87.5) 0.287y
Cumulative dose of norepinephrine (mg) 1045 (549; 1854) 1587 (1378; 3436) 0.023

Intraoperative dose of norepinephrine (mg kg1 min1) 0.06 (0.04; 0.09) 0.11 (0.06; 0.16) 0.028
Patients with inotropic drugs indicated, n (%) 1 (3.2) 2 (12.5) 0.264y
Sum of estimated intraoperative blood loss (mL) 760 (450; 1675) 1500 (600; 2200) 0.125

Sum of diuresis (mL kg1 min1) 1.90 (0.80; 3.00) 0.64 (0.37; 1.80) 0.009
FIGO¼Fe´de´ration Internationale de Gyne´cologie et d’Obste´trique, HAS¼ high ascites, NLAS¼ none or low ascites, POSSUM¼Physiologic and
Operative Severity Score for the enumeration of Mortality and Morbidity.
s.
and
Hunsicker et al Medicine  Volume 94, Number 49, December 2015cardiac output, the combination of higher HR and lower SV
suggests alterations of circulatory blood flow in patients with
high amount of ascites.
In the HAS group, the fluid demands increased steadily
during the first 1.5 h after beginning of surgery reflected by a
continuously decreasing time to reindication of fluid optimiz-
ation (TTRI), whereas simultaneously stroke volume could not
Data are shown as median (25%; 75%) quartiles or as n (%) patient
P values calculated using the exact Wilcoxon–Mann–Whitney test
be maintained at baseline values resulting in hemodynamic
instability after 1.5 h of surgery. From a rational view, detri-
mental effects of MA on the circulation are due to the impact on
6 | www.md-journal.comfluid homeostasis prior and during surgery while considering
consequences of loss of MA following laparotomy. In patients
with MA, the exudative loss is predominantly caused by a
massive increase of vascular permeability and neovasculariza-
tion of small peritoneal blood vessels.16 Vascular endothelial
growth factor released by tumor cells is a major determinant
altering vascular permeability and promoting uncontrolled vas-
Fisher’s exact testy as appropriate.cular growth.17 The combination of substantial neoangionesis
of nonmatured peritoneal blood vessels with massive hyper-
permeability results in a substantial fluid shift from the
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No ascites or 
ascites <500ml (NLAS)
Ascites >500ml (HAS)
FIGURE 3. Intraoperative course of cardiac output (A), heart rate (B), stroke volume (C), corrected flow time (D), mean arterial pressure
(E), and central venous pressure (F). Data are shown as median and (25%; 75%) quartiles. Results of the nonparametric analysis with
respect to time courses are indicated. P Values calculated using NparLDy or GEEz. Adjusted for randomized study groups of the main
study.

Adjusted for randomized study groups of the main study and beta blocker therapy. GEE¼general estimating equation,
Medicine  Volume 94, Number 49, December 2015 Hemodynamic Consequences of Malignant Ascites in EOC Surgeryintravascular space to the peritoneal cavity and is considered as
a major mechanism for ongoing fluid loss during surgery and
might explain the substantial fluid demands in the high ascites
group. As patients with MA commonly present with elevated
intraabdominal pressures,18 the rapid pressure decrease follow-
ing laparotomy is hypothesized to augment the fluid shift due to
an increase of intravascular to peritoneal cavity hydrostatic
pressure gradient and to cause changes in splanchnic circula-
tion. A rapid decrease of external pressure on the splanchnic
vasculature is supposed to be followed by a reactive release of
vasodilative mediators increasing splanchnic arterial blood
flow. In this regard, an increased arterial splanchnic inflow
results not only in an elevated hydrostatic pressure in the
peritoneal blood vessels but causes a blood pooling within
the splanchnic veins due to the flow–pressure–volume relation
in the splanchnic circulation.19,20 Blood pooling decreases
NparLD¼nonparametric analysis for longitudinal data.mean systemic filling pressure and results in a reduced venous
return pressure gradient.19,21 In this respect, an impaired venous
return might explain the rapid onset of a decreasing stroke
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.volume after start of surgery in the high ascites group whereas
there were no signs for a compensation by release of external
pressure of the large intra-abdominal veins. In addition, the low
albumin concentration in patients with high amounts of ascites
might affect circulatory blood flow. As blood albumin contrib-
utes up to 75% to 80% to maintain the colloid osmotic pressure,
a reduced albumin concentration prior surgery is supposed to
affect intravascular and tissue fluid distribution, which might
contribute to a decreased intravascular volume at the time of
surgery.22
Knowledge on the appropriate type of fluid replacement in
patients with high amounts of MA undergoing cytoreductive
surgery is crucial but still limited.23 Our findings show that
clinically relevant associations of the type of fluid replacement
with hemodynamic consequences were particularly observed in
the high ascites group, in which administering artificial infusion
solutions was associated to an impaired circulatory flow and
impaired hemodynamic stability, whereas the administration of
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Hunsicker et al Medicine  Volume 94, Number 49, December 2015reflected by increases of SV, prolongations of TTRI, and
decreases of HR and NE administration. To date, FFP is used
frequently during surgery, but its efficacy is controversial
whereas its use involves several serious risks.24,25 Currently,
there is an ongoing debate about the effect of transfusion-related
and time to reindication of a fluid challenge (D). Data are shown
analysis with respect to time courses are indicated. P values calcula
the main study. GEE¼general estimating equation, NparLD¼nonimmune modulation of different blood products but to date,
there is no conclusive evidence that transfusion of FFP in
patients undergoing cancer surgery promotes cancer recurrence
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FIGURE 5. Forest plot visualizing the association of administered infu
volume, norepinephrine dose, and time to reindication by presenting a
longitudinal data with adjustment considering multiple measurement
ratios of heart rate, stroke volume, norepinephrine, and time to reindic
min, respectively. GEE¼general estimating equation, OR¼odds ratio
8 | www.md-journal.comand decreases overall survival.26–28 With respect to the peri-
operative period, the latest guideline published by the American
Association of Blood Banks (AABB) has recommended using
FFP only during massive transfusion after trauma and in
patients with warfarin therapy-related intracranial hemor-
median and (25%; 75%) quartiles. Results of the nonparametric
using NparLDy or GEEz.Adjusted for randomized study groups of
rametric analysis for longitudinal data.rhage.29 However, they could not recommend for or against
transfusion of plasma for patients undergoing surgery in the
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sion solutions and fresh frozen plasma with heart rate and stroke
djusted odds ratios (OR) obtained from GEE regression analysis for
s per patient. Odds ratios are drawn on a logarithmic scale. Odds
ation are scaled for changes of min1, mL, 0.01mgkg1 min1 and
s.
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addressing this practice was of very low quality.29 In this regard,
our findings suggest that FFP transfusion could help recovering
hemodynamic stability in patients with high amount of malig-
nant ascites undergoing cancer surgery in whom intravenous
infusion solutions could not prevent from hemodynamic
deterioration. In this context, the link between FFP transfusion
and reconstitution of hemodynamic stability is hypothesized to
be multifactorial related. In contrast to any intravenous infusion
solution, FFP contains significant content of proteins while the
percentage of albumin of 60% is comparable to normal
serum.30 In addition, FFP has a secondary hyperosmolal effect
due a rapid metabolism of the preservation solutions’ citrate to
hydrogen carbonate ions in the liver with a 1:3 ratio.31 Further-
more, whereas FFP contains adequate levels of hemostatic
factors,32 recent in vitro and in vivo studies indicate that
FFP transfusion is related to a reduced vascular endothelial
cell permeability and to a decreased expression of endothelial
adhesion markers.33–35 These findings were recently confirmed
in critical ill patients indicating the role of FFP transfusion to
preserve endothelial integrity.36 In summary, to date, the recon-
stitution of hemodynamic stability observed after FFP admin-
istration in patients with MA sustaining substantial exudative
losses during surgery is supposed to be attributed by replacing
albumin content in circulating blood volume, administering a
secondary hyperosmolal solution, and restoring and maintain-
ing endothelial integrity.
The study has some limitations. First, post-hoc analyses of
randomized controlled trials often have to handle heterogeneous
data and the interventions usually constitute the most important
confounding factors. In our case, the main study revealed
significant differences in stroke volume, corrected flow time,
and fluid administration between the crystalloid and colloid
intervention groups. However, using advanced statistical
methods allowed us to adjust the analyses of time courses of
all investigated endpoints for the intervention groups of the
main study providing valid results for this post hoc analysis and
minimizing the potential to undermine the conclusions. Second,
implications regarding the beneficial effects of FFP with respect
to hemodynamic stability have to be drawn carefully as this
study was not designed to compare FFP with intravenous
infusion solutions and consequently FFP transfusion was started
when maximum dose of the study fluid was reached whereas the
findings are based on regression analysis not allowing simply
stating causation. However, when revealing interesting associ-
ations a potential causal relationship has to be considered,
discussed, further investigated, and eventually confirmed
or rejected.
In summary, malignant ascites >500mL is related to
increased fluid demands and substantial alterations in circu-
latory blood flow during cancer surgery resulting in hemo-
dynamic instability after 1.5 h of surgery. Fresh frozen
plasma administration could help recovering hemodynamic
stability in patients with malignant ascites >500mL, in
whom intravenous infusion solutions could not prevent from
hemodynamic deterioration.
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